Overview

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

Phase III, open-labeled, randomized and multicenter clinical trial to evaluate the superiority of romiplostim plus dexamethasone vs dexamethasone alone in patients with newly diagnosed primary immune thrombocytopenia

Phase:

Phase 3

Details

Lead Sponsor:

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate